Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Esther De La Cuesta"'
Autor:
Naoko Higuchi, Yuko Honda, Yuhki Koga, Hiroshi Asai, Hiroaki Ono, Wakako Kato, Kentaro Nakashima, Esther De La Cuesta, Toshiaki Tsujino, Hidetaka Yamamoto, Koichi Kusuhara, Masanori Hisaoka, Shouichi Ohga
Publikováno v:
Pediatric Blood & Cancer.
Autor:
Hiroaki Goto, Laura Dima, Steven G. DuBois, Ricarda Norenberg, Jordan R. Hansford, Esther De La Cuesta, Juneko E. Grilley-Olson, Ingrid Øra, David S. Hong, Theodore W. Laetsch, Karsten Nysom, Joanna Stefanowicz, Martin Højgaard, Valentina Boni, Hyoung Jin Kang, Julia C. Chisholm, Makoto Tahara, Birgit Geoerger, François Doz, Soledad Gallego-Melcon, David S. Ziegler, Alexander Drilon, Cornelis M. van Tilburg, Hyun Cheol Chung, Anne Thorwarth, Igor T. Gavrilovic, Antoine Italiano, Michael Capra, Sébastien Perreault, Nicolas U. Gerber
Publikováno v:
Neuro-Oncology. 24:997-1007
Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety o
Autor:
Sébastien Perreault, Alexander Drilon, Ulrik N Lassen, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Igor T Gavrilovic, Ricarda Norenberg, Vadim Bernard-Gauthier, Esther De La Cuesta, Theodore W Laetsch, François Doz, Cornelis M Van Tilburg
Publikováno v:
Neuro-Oncology. 24:vii87-vii87
BACKGROUND Larotrectinib is a highly selective TRK inhibitor that demonstrated an objective response rate (ORR) of 30% and a 24-week disease control rate (DCR) of 73% across 33 evaluable adult and pediatric patients with TRK fusion primary CNS tumors
Autor:
Karsten Nysom, François Doz, Birgit Geoerger, Ingrid Øra, Sebastien Perreault, Ricarda Norenberg, Marc Fellous, Esther De La Cuesta, Theodore W Laetsch, Cornelis M van Tilburg
Publikováno v:
Neuro-Oncology. 24:i64-i64
INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumours. Larotrectinib, a highly selective TRK inhibitor, demonstrated an objective response rate (ORR) of 75% across 206 evaluable patients with
Autor:
François Doz, Cornelis M van Tilburg, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Valentina Boni, Julia Chisholm, Hyun Cheol Chung, Steven G DuBois, Soledad Gallego Melcón, Nicolas U Gerber, Hiroaki Goto, Juneko E Grilley-Olsen, Jordan R Hansford, David S Hong, Antoine Italiano, Hyoung Jin Kang, Michael Capra, Johannes H Schulte, Joanna Stefanowicz, Makoto Tahara, David S Ziegler, Igor T Gavrilovic, Ricarda Norenberg, Laura Dima, Esther De La Cuesta, Theodore W Laetsch, Alexander Drilon, Sébastien Perreault
Publikováno v:
Neuro-Oncology. 23:vi73-vi74
BACKGROUND NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a first-in-class, highly selective TRK inhibitor approved for patients with TRK fusion cancer, with a 75% objective response rate (ORR) in 206 eval
Autor:
Marc Fellous, Gilles Vassal, Antoine Italiano, Carsten Bokemeyer, Esther De La Cuesta, Marisca Marian, Florian Hiemeyer
Publikováno v:
JCO Precision Oncology
PURPOSE Neurotrophic tyrosine receptor kinase (NTRK) gene fusions encode oncogenic, chimeric tropomyosin receptor kinase (TRK) proteins. Larotrectinib, an approved TRK inhibitor, is efficacious in locally advanced or metastatic (adv/met) TRK fusion c
Autor:
Magnus Sabel, Ingrid Øra, Magnus Tisell, Frida Abel, Helene Sjögren, Simon Keane, Jonas Nilsson, Thomas Olsson Bontell, Katarina Ejeskär, Lily Deland, Henrik Fagman, Esther De La Cuesta
Publikováno v:
Cancer Biology & Therapy
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Here we report a case of an 11-year-old girl with an inoperable tumor in the optic chiasm/hypothalamus, who experienced several tumor progressions despite three lines of chemotherapy treatment. Routine clinical examination classified the tumor as a B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::652d20ceec10a176f5086a55978ea15a
http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-19649
http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-19649
Publikováno v:
Pediatric Blood & Cancer. 67
Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fus
Autor:
David S. Ziegler, Hiroaki Goto, Julia C. Chisholm, Juneko E. Grilley-Olson, Esther De La Cuesta, Theodore W. Laetsch, Karsten Nysom, Joanna Stefanowicz, Steven G. DuBois, Hyoung Jin Kang, Jordan R. Hansford, L. Dima, François Doz, Ricarda Norenberg, Cornelis M. van Tilburg, Nicolas U. Gerber, Johannes H. Schulte, Birgit Geoerger, Michael Capra, Valentina Boni, Makoto Tahara, Sébastien Perreault, Ingrid Øra
Publikováno v:
Neuro-Oncology
Background NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with TRK fusion cancer, with an objective response rate (ORR) of 78% across multiple no
Autor:
Karsten Nysom, Ricarda Norenberg, Alexander Drilon, Birgit Geoerger, Esther De La Cuesta, Cornelis M. van Tilburg, L. Dima, Francois P. Doz, Ingrid Øra, Igor T. Gavrilovic, Sébastien Perreault
Publikováno v:
Journal of Clinical Oncology. 39:2002-2002
2002 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions are oncogenic drivers in various tumor types, including central nervous system (CNS) tumors. Larotrectinib is a first-in-class, highly selective TRK inhibitor approved for th